Cyberounds Logo
July 20, 2019 | LOGIN | REGISTER | HELP | 
email a friend print Bookmark and Share
Targeted Therapies for Ovarian Cancer
CME credit is no longer available for this conference.
Frederick Sweet, Ph.D.

Frederick Sweet, Ph.D. is Professor of Reproductive Biology in Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri.

Dr. Sweet reports no commercial conflicts of interest.

Release Date: 11/12/2007
Termination Date: 11/12/2010

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Learning Objectives
Upon completion of this Cyberounds®, you should be able to:
  • Discuss the diverse concepts that constitute targeted therapy
  • Describe recent basic and clinical progress from research on these novel therapies
  • Discuss how near or far we are from having more effective new therapies for ovarian cancer "just around the corner."

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
Please click below to accept the terms of this CME activity